# Who Is Actually Funding Cannabinoid Research Today?

> AI written. This is a column post generated from The Dime's episode catalogue, not a transcript and not written by the hosts.

Funding has shifted from government agencies studying only cannabis harms to a mix of complementary medicine divisions, universities, and corporate capital like British American Tobacco backing therapeutic trials. The infrastructure (journals, conferences, degree programs) now exists to support real science, but researchers say the field still needs far more people and money.

- Author: Isaac Burner, AI analyst for The Dime (AI written, reviewed before publishing)
- Published: 2026-10-13
- Canonical: https://www.dimepodcast.com/answers/who-is-funding-cannabinoid-research
- Column: https://www.dimepodcast.com/answers
- Topics: [Medical & Research](https://www.dimepodcast.com/topics/medical-and-research), [Capital Raising & Funding](https://www.dimepodcast.com/topics/capital-raising-and-funding), [Data & Technology](https://www.dimepodcast.com/topics/data-and-technology)

## Sources

Episodes of The Dime Podcast this answer is drawn from.

- [Cannabis Was Medicine. Now the Proof Is Catching Up, ft. Joel Stanley and Dr. Marcel Bonn-Miller](https://www.dimepodcast.com/episodes/cannabis-was-medicine-now-the-proof-is-catching-up-ft-joel-stanley-and-dr-marcel-bonn-miller) with Joel Stanley and Dr. Marcel Bonn-Miller
  Markdown: https://www.dimepodcast.com/episodes/cannabis-was-medicine-now-the-proof-is-catching-up-ft-joel-stanley-and-dr-marcel-bonn-miller.md
- [How Minor Cannabinoids are Made: Synthetic vs Biosynthetic ft. Shane Johnson](https://www.dimepodcast.com/episodes/how-minor-cannabinoids-are-made-synthetic-vs-biosynthetic-ft-shane-johnson) with Shane Johnson
  Markdown: https://www.dimepodcast.com/episodes/how-minor-cannabinoids-are-made-synthetic-vs-biosynthetic-ft-shane-johnson.md

## Answer

For most of cannabinoid science's history, the money only flowed one direction: toward proving harm. Dr. Marcel Bonn-Miller, who has done cannabinoid research for about 23 years, said that in the early days nearly everyone in the field studied harms, because that's where the funding was, and nobody was funding therapeutic research. That has changed, but not evenly, and not completely, as he and Joel Stanley discussed on [Cannabis Was Medicine. Now the Proof Is Catching Up](/episodes/cannabis-was-medicine-now-the-proof-is-catching-up-ft-joel-stanley-and-dr-marcel-bonn-miller).

## The funding base has diversified

Bonn-Miller said there's now a lot more funding coming from organizations beyond the National Institute on Drug Abuse, which historically only funded studies on cannabis-related harms. Complementary and alternative medicine divisions are now funding cannabinoid therapeutics research, including a growing focus on patients 65 and older, with the University of Colorado Boulder publishing studies in that area. Universities have built out real infrastructure around this too: multiple academic journals dedicated to cannabis research now exist, along with several conferences beyond the International Cannabinoid Research Society, and accredited degree and certificate programs, including one at Thomas Jefferson University that Bonn-Miller helped build the curriculum for.

## Corporate capital is entering through drug development, not consumer brands

The clearest sign of where serious money is going is Ozna Biosciences' lead drug candidate, AJA-001, a full-spectrum CBD/THC formulation targeting irritability and aggression in autism spectrum disorder. Joel Stanley, founder of Ozna and formerly founding CEO of Charlotte's Web, said the drug is partly funded by a $15 million investment from British American Tobacco through a partnership called Deloria. That's tobacco capital underwriting FDA-grade botanical drug development, not a wellness product line. It's a different funding logic than the consumer cannabinoid market, where companies like BayMedica fund their own biosynthesis and chemical synthesis R&D to produce minor cannabinoids such as CBC and THCV at commercial scale, as Shane Johnson described on [How Minor Cannabinoids are Made](/episodes/how-minor-cannabinoids-are-made-synthetic-vs-biosynthetic-ft-shane-johnson).

## The field is still understaffed relative to the work in front of it

Bonn-Miller said researchers who used to study alcohol are now shifting into cannabis, which is a good sign, but he also said there's still a mountain to climb and the field needs more people doing the work, because each individual cannabinoid represents years of research on its own. That's the real constraint right now. It isn't that nobody will fund cannabinoid science anymore. It's that the number of qualified people and standardized processes hasn't caught up to the number of compounds worth studying.

For an operator thinking about where to put research dollars, the lesson is to go where the funding infrastructure already exists rather than trying to build it from scratch. Partnering with university programs, publishing through the dedicated journals that now exist, and courting therapeutics-focused capital (not just consumer brand investors) are all more viable paths now than they were even a decade ago. But don't expect speed. Bonn-Miller's point stands: each cannabinoid is its own multi-year research project, and there simply aren't enough hands on deck yet.

## Related questions

### Has government funding for cannabinoid research changed?

Dr. Marcel Bonn-Miller said funding now comes from more sources beyond the National Institute on Drug Abuse, which historically only funded harm-focused studies, with complementary and alternative medicine divisions now funding therapeutic cannabinoid research.

### What academic infrastructure exists for cannabinoid research now?

Bonn-Miller said there are now multiple academic journals dedicated to cannabis research, several conferences beyond the International Cannabinoid Research Society, and accredited university programs offering certificates and degrees, including one at Thomas Jefferson University.

### Is corporate money funding cannabinoid drug development?

Yes. Joel Stanley said British American Tobacco invested $15 million through a partnership called Deloria to help fund Ozna Biosciences' AJA-001 autism drug candidate through Phase 2 trials.

### Is the cannabinoid research field adequately staffed?

No. Bonn-Miller said there's still a mountain to climb and the field needs more researchers, noting that each individual cannabinoid represents years of dedicated study on its own.


---

Markdown variant of any episode, guest, newsletter, answer or topic page on this site: add .md to its URL.
Site index: https://www.dimepodcast.com/llms.txt. Complete catalogue: https://www.dimepodcast.com/llms-full.txt
